Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: M&A with TPL
Well, here's a thought. Perhaps a merger with TPL was not possible because it was too difficult to determine the value of TPL's IP. But if PTSC has its own IP, which was more of less equal in terms of number of patents and potential, perhaps a merger of equals becomes less problematic? It sounds almost too trivial to be true, but then why waste your time on investments that have no chance of happening near term, and will not achieve the stated goals? They looked at not one, not two, but several IP portfolios. Why? Opty
Share
New Message
Please login to post a reply